BAXTER INTERNATIONAL INC
About BAXTER INTERNATIONAL INC
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $11.2B
- Net income
- -$957.0M
- Total assets
- $20.1B
- Market cap
- $10.0B
- Gross margin
- 30.1%
- Operating margin
- -2.7%
- Net margin
- -8.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $11.2B
- Cost of revenue
- $7.9B
- Gross profit
- $3.4B
- Operating expenses
- $3.7B
- Operating income
- -$308.0M
- Income tax
- $395.0M
- Net income
- -$957.0M
- EPS (basic)
- $-1.87
- EPS (diluted)
- $-1.87
Balance sheet
- Total assets
- $20.1B
- Current assets
- $6.9B
- Total liabilities
- $14.0B
- Current liabilities
- $3.0B
- Shareholders’ equity
- $6.1B
Cash flow
- Operating cash flow
- $845.0M
- Investing cash flow
- $2.8B
- Financing cash flow
- -$4.2B
- Net cash flow
- -$530.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $10.0B
- EPS (diluted)
- $-1.87
- Dividend yield
- 0.2%
- Shares outstanding
- 492.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 15, 1961
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $957.0M in FY2025.
- Revenue declined 4% from FY2020 to FY2025.
- Gross margin of 30.1%, net margin -8.5%.
- Trading 36% below its 52-week high.
- Pays a dividend yielding about 0.2% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review BAXTER INTERNATIONAL INC.
Write a review
News about BAXTER INTERNATIONAL INC
News & sentiment via Polygon.io
